Fast development of high quality material - From medicinal chemistry programme to GLP tox studies material

Aprea recently submitted an IND application for APR-548 - an important milestone in their development efforts. In collaboration with Recipharm they went through an incredibly fast process, from the start of the medicinal chemistry programme to delivery of kilogram quantities formulated for GLP toxicology studies, the overall research and development activity spanned approximately three years. Seamless transfer of analytical methods and knowledge about the compound to Recipharm’s development site in Solna enabled rapid pharmaceutical development of the phase I formulation and subsequent manufacture of clinical trial material (CTM).

Register below to download the full Case study.